Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
RLYB Rallybio
10.670
-0.060-0.56%
Post Mkt Price
10.67000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
67.28% 17.62M 11.65% 14.32M 80.41% 45.65M 22.07% 12.31M
Selling and administrative expenses
101.43% 7.48M 76.13% 6.67M 144.22% 18.74M 139.93% 6.22M
-General and administrative expense
101.43% 7.48M 76.13% 6.67M 144.22% 18.74M 139.93% 6.22M
Research and development costs
48.69% 10.14M -15.37% 7.65M 52.63% 26.91M -18.69% 6.09M
Operating profit
-67.28% -17.62M -11.65% -14.32M -80.41% -45.65M -22.07% -12.31M
Net non-operating interest income expense
1976.92% 270K 1285.71% 97K -63.93% 44K -20% 12K
Non-operating interest income
1976.92% 270K 470.59% 97K -68.42% 54K -55.56% 12K
Non-operating interest expense
-- 0 -- 0 -79.59% 10K -- 0
Other net income (expense)
170.42% 100K 370.83% 113K -60.17% 96K 60.29% 109K
Other non- operating income (expenses)
170.42% 100K 370.83% 113K -60.17% 96K 60.29% 109K
Income before tax
-61.79% -17.25M -10.28% -14.11M -82.47% -45.51M -21.87% -12.19M
Income tax
0 0
Earnings from equity interest net of tax
27.78% -338K 19.09% -390K 1.12% -1.51M 56.53% -223K
Net income
-58.02% -17.58M -9.21% -14.5M -77.76% -47.01M -18.04% -12.42M
Net income continuous Operations
-58.02% -17.58M -9.21% -14.5M -77.76% -47.01M -18.04% -12.42M
Minority interest income
Net income attributable to the parent company
-58.02% -17.58M -9.21% -14.5M -77.76% -47.01M -18.04% -12.42M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-58.02% -17.58M -9.21% -14.5M -77.76% -47.01M -18.04% -12.42M
Basic earnings per share
-57.52% -0.57 20% -0.48 -21.05% -1.84 11.17% -0.42
Diluted earnings per share
-57.52% -0.57 20% -0.48 -21.05% -1.84 11.17% -0.42
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
CEO: MacKay Ph.D., Martin W.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top